NR-160，5MG，SML3311-5MG，Sigma

Biochem/physiol Actions

Active site-targeting, potent and selective histone deacetylase 6 inhibitor that augments the cytotoxicity ofbortezomib, epirubicin, and daunorubicin.
NR-160 is an active site-targeting, potent and selective histone deacetylase 6 inhibitor (HDAC6 IC50 = 30 nM; IC50 >2 μM against HDAC1/2/3/4/8) that upregulates HL60 cellular acetylation of HDAC6 substrate α-tubulin (2.5 μM), but not that of class I HDACs substrate histone H3. NR-160 augments the apoptosis induction by the proteasome inhibitor bortezomib (0.6/1.2 nM BTZ with 2.5/5.0 μM NR-160; HL60) and significantly enhances the cytotoxicity of DNA-intercalating anti-cancer drugs epirubicin and daunorubicin (2.5 or 5.0 μM NR-160 in combination with 10 nM of either compound to T-ALL line HSB-2).